Rajesh Odedra - Concepedia

Author

Rajesh Odedra

Also Known As

Odedra, R., Odedra, Rajesh, R Odedra, R. M. Odedra, R. Odedra, R.M Odedra, R.M. Odedra, RAJESH ODEDRA, Raj Odedra, Rajesh Odedra

149

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)University of Liverpool University of Manchester AstraZeneca (United States)AstraZeneca (France)

About

Rajesh Odedra is an author at AstraZeneca (United Kingdom) specializing in medicine, radiation oncology, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	19	1.5K
2	Engineering	12	14	550
3	Natural Sciences	5	5	759
4	Health Sciences	4	4	222
5	Education	1	1	28

Rajesh Odedra

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis Robert W. Wilkinson, Rajesh Odedra, Simon P. Heaton, Clinical Cancer Research	2007	355
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent Kevin M. Foote, J. Willem M. Nissink, Thomas M. McGuire, Journal of Medicinal Chemistry Kinase Ataxia TelangiectasiaCell DeathMolecular BiologyPharmacotherapyCompound 2	2018	313
Discovery, Synthesis, and <i>in Vivo</i> Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase Andrew Mortlock, Kevin M. Foote, Nicola M. Heron, Journal of Medicinal Chemistry Pharmaceutical ScienceSelective InhibitorsPharmacotherapyAurora BChemical Biology	2007	270
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo Susan Ashton, Young Ho Song, Elaine Cadogan, Science Translational Medicine	2016	213
Discovery of 4-{4-[(3<i>R</i>)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1<i>H</i>-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity Kevin M. Foote, Kevin Blades, Anna Cronin, Journal of Medicinal Chemistry Compound 6PharmacotherapyPharmaceutical ChemistryTumor BiologyMedicinal Chemistry	2013	213
Multiplex PCRs for Identification of <i>Escherichia coli</i> Virulence Genes M.A. Pass, Rajesh Odedra, Roger M. Batt Journal of Clinical Microbiology E. ColiMultiplex PcrsMultiplex ReactionsPathogen DetectionEngineering	2000	171
CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells David Krige, Lindsey Needham, Lindsay J. Bawden, Cancer Research	2008	116
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models Sarah V. Holt, Armelle Logié, Rajesh Odedra, British Journal of Cancer	2012	111
Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors Frédéric Jung, Georges Pasquet, Christine Lambert‐van der Brempt, Journal of Medicinal Chemistry Planar ConformationPharmacotherapySelective Aurora AHeterocycle ChemistryChemical Biology	2006	92
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models Lenka Oplustil O’Connor, Stuart L. Rulten, Aaron Cranston, Cancer Research Chemoprevention StrategyParp3 InhibitionPharmacotherapyCancer BiologyTumor Biology	2016	90

Page 1